APAC is under clinical development by Aplagon and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase II drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how APAC’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

APAC overview

Recombinant protein is under development for the treatment of thrombosis, chronic kidney disease and critical limb ischemia. The drug candidate is a heparin-containing molecule conjugated to a plasma protein which acts locally decreasing the bleeding risk and has both anti-platelet and anticoagulant (APAC) activity. It acts by targeting von Willebrand factor. It is administered through intravenous bolus route.

Aplagon overview

Aplagon operates as a pharmaceutical company that develops proprietary, vascular injury targeting and locally acting, potent antithrombotic products. The company develops antithrombotic drug therapy to prevent and treat blood clots or thrombotic occlusions. Its APACs targets platelets and the coagulation system and prevents intervention related thrombosis and later vascular wall thickening. Aplagon’S APACS also manages vascular complications associated with blood vessel interventions, such as vascular surgery or balloon angioplasty. Its products mimic the natural cell derived heparin proteoglycans that have both antiplatelet and anticoagulant properties. The company’s APAC therapeutic candidate is in late stage preclinical development. It also conducts research and development to advance its products. Aplagon is headquartered in Helsinki, Finland .

For a complete picture of APAC’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.